aTyr Pharma (LIFE) Competitors

bluebird bio (NASDAQ:BLUE) and aTyr Pharma (NASDAQ:LIFE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, community ranking, media sentiment, earnings, dividends and profitability.

Do analysts rate BLUE or LIFE?

bluebird bio presently has a consensus target price of $5.87, suggesting a potential upside of 536.04%. aTyr Pharma has a consensus target price of $23.67, suggesting a potential upside of 1,379.17%. Given bluebird bio's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than bluebird bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bluebird bio	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
aTyr Pharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Which has more volatility & risk, BLUE or LIFE?

bluebird bio has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.

Which has higher valuation and earnings, BLUE or LIFE?

aTyr Pharma has lower revenue, but higher earnings than bluebird bio. aTyr Pharma is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bluebird bio	$3.60M	28.03	-$266.58M	-$0.74	-1.25
aTyr Pharma	$350K	310.58	-$50.39M	-$0.96	-1.67

Is BLUE or LIFE more profitable?

aTyr Pharma has a net margin of 0.00% compared to aTyr Pharma's net margin of -419.64%. aTyr Pharma's return on equity of -34.32% beat bluebird bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bluebird bio	-419.64%	-34.32%	-14.44%
aTyr Pharma	N/A	-49.84%	-39.12%

Does the MarketBeat Community favor BLUE or LIFE?

bluebird bio received 615 more outperform votes than aTyr Pharma when rated by MarketBeat users. Likewise, 71.78% of users gave bluebird bio an outperform vote while only 61.40% of users gave aTyr Pharma an outperform vote.

Company	Underperform	Outperform
bluebird bio	Outperform Votes 1035 71.78%	Underperform Votes 407 28.22%
aTyr Pharma	Outperform Votes 420 61.40%	Underperform Votes 264 38.60%

Does the media refer more to BLUE or LIFE?

In the previous week, bluebird bio had 8 more articles in the media than aTyr Pharma. MarketBeat recorded 10 mentions for bluebird bio and 2 mentions for aTyr Pharma. bluebird bio's average media sentiment score of 0.80 beat aTyr Pharma's score of 0.07 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
bluebird bio	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
aTyr Pharma	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of BLUE or LIFE?

87.4% of bluebird bio shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 2.1% of bluebird bio shares are owned by company insiders. Comparatively, 3.7% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

bluebird bio beats aTyr Pharma on 10 of the 18 factors compared between the two stocks.